Drug Fix: What We Learned From The First Medicare Price Negotiation List, Pepaxto Withdrawal Update

Pink Sheet reporters and editors consider lessons and next steps after the first list of drugs subject to Medicare price negotiations was released (:34) and discuss Oncopeptides’ Pepaxto facing withdrawal under the US FDA’s new and potentially faster process (22:44). More On The Medicare Price Negotiation List From The Pink Sheet Litigation Against Medicare Price Negotiation Gains Four Potential New Plaintiffs: https://pink.pharmaintelligence.informa.com/PS148778/Litigation-Against-Medicare-Price-Negotiation-Gains-Four-Potential-New-Plaintiffs Medicare Negotiation List Surprises Highlight The Importance Of Current Spending Data: https://pink.pharmaintelligence.informa.com/PS148781/Medicare-Negotiation-List-Surprises-Highlight-The-Importance-Of-Current-Spending-Data Patent Cliff Likely Accelerated By Two Years For Most Drugs On Medicare Price Negotiation List: https://pink.pharmaintelligence.informa.com/PS148775/Patent-Cliff-Likely-Accelerated-By-Two-Years-For-Most-Drugs-On-Medicare-Price-Negotiation-List Price Negotiation Purgatory: Upcoming Biosimilars Couldn’t Keep Stelara, NovoLog Off The List: https://pink.pharmaintelligence.informa.com/PS148776/Price-Negotiation-Purgatory-Upcoming-Biosimilars-Couldnt-Keep-Stelara-NovoLog-Off-The-List Timetable For Medicare Price Negotiation Of The First 10 Drugs (And Beyond): https://pink.pharmaintelligence.informa.com/PS148760/Timetable-For-Medicare-Price-Negotiation-Of-The-First-10-Drugs-And-Beyond CMS Seeking Patient Comments On Negotiated Drugs Similar To US FDA’s PFDD Program: https://pink.pharmaintelligence.informa.com/PS148773/CMS-Seeking-Patient-Comments-On-Negotiated-Drugs-Similar-To-US-FDAs-PFDD-Program Big Rebates Already A Big Factor For Drugs On Medicare Negotiation List: https://pink.pharmaintelligence.informa.com/PS148774/Big-Rebates-Already-A-Big-Factor-For-Drugs-On-Medicare-Negotiation-List Price Negotiation And The GLP1 Class: Trulicity Lucky To Be A BLA: https://pink.pharmaintelligence.informa.com/PS148794/Price-Negotiation-And-The-GLP1-Class-Tru